Key statistics
As of last trade, Polyrizon Ltd (PLRZ:NAQ) traded at 13.77, 378.13% above the 52 week low of 2.88 set on Nov 26, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 13.20 |
|---|---|
| High | 14.40 |
| Low | 13.00 |
| Bid | 13.75 |
| Offer | 14.13 |
| Previous close | 13.25 |
| Average volume | 104.85k |
|---|---|
| Shares outstanding | 1.59m |
| Free float | 1.28m |
| P/E (TTM) | -- |
| Market cap | 21.95m USD |
| EPS (TTM) | -582.43 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
- Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
- Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
- Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
- Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
- Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
- Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
- Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
- As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated
- Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
- Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
More ▼
